This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEH290Y2_L.jpg
WASHINGTON (Reuters) – The United States plans to double its order of the single-shot Johnson & Johnson (NYSE:JNJ) coronavirus vaccine, procuring an additional 100 million doses, a White House official said on Wednesday.
President Joe Biden will direct the Department of Health and Human Services to secure the additional supply, the official said, speaking on condition of anonymity.
Biden is likely to highlight the issue at a meeting with the chief executives of J&J and Merck & Co later on Wednesday. Merck has agreed to partner with J&J to produce its vaccine.
The United States has already paid over $1 billion for 100 million doses from J&J and had an option to purchase an additional 200 million doses.
Biden has sought to speed up the vaccination process since taking office on Jan. 20. The pandemic has killed more than 528,000 people in the United States alone.
J&J’s manufacturing has been slower than hoped, and it was not expected to be able to deliver any vaccine doses this week. It is expected to resume shipments later in March.
The company indicated that another vaccine purchase by the U.S. administration had not been finalized.
“Last August, Johnson & Johnson signed an agreement with the U.S. government to deliver 100 million doses of our COVID vaccine, and we are on track to meet that commitment,” spokesman Jake Sargent said.
“The U.S. Government has the option to purchase additional doses under a subsequent agreement. We look forward to any future discussions with the U.S. Government and to participating in the event at the White House later today,” he added.
J&J has come up short on its shipments to the United States this month, promising to deliver only 20 million of the 37 million doses it had originally promised to have ready by now.
Merck will help with the final manufacturing steps called fill and finish – expected to be up and running in May – and the production of the vaccine itself. J&J, which has committed to producing 1 billion doses this year, also said it is continuing to seek more manufacturing partners.
The United States approved the Pfizer/BioNTech and Moderna (NASDAQ:MRNA) Inc vaccines in December, and those companies have been working to increase their production since then.
Pfizer (NYSE:PFE) and Moderna have committed to supplying the country with 120 million doses and 100 million doses, respectively, by the end of March. They have agreed to supply 300 million doses each by the end of July.
As of Tuesday morning, more than 123 million doses of coronavirus vaccines had been distributed in the United States and 93.7 million shots had been administered, according to data from the U.S. Centers for Disease Control and Prevention.
